Antiparasitic Medication Shows Potential to Halt Aggressive Skin Cancer Growth

Recent research from the University of Arizona suggests that a common antiparasitic drug, pyrvinium pamoate, traditionally used to treat pinworms, may have promising effects against Merkel cell carcinoma (MCC), an aggressive and rare form of skin cancer. MCC is known for its rapid growth and limited response to current therapies such as surgery, radiation, and immunotherapy, highlighting the urgent need for new effective treatments.

In laboratory studies, pyrvinium pamoate was observed to inhibit the proliferation of cancer cells and reverse neuroendocrine features characteristic of MCC. Remarkably, in mouse models, the drug significantly reduced tumor growth, indicating its potential as a therapeutic agent.

The drug’s anti-tumor effects are believed to stem from its ability to inhibit the Wnt signaling pathway, a key driver in the transformation of normal cells into cancerous ones. Since MCC development has been linked to the Merkel cell polyomavirus (MCPyV), and given that tumors often hijack pathways similar to those parasites exploit, scientists consider the possibility that antiparasitic drugs could target these common mechanisms.

Dr. Megha Padi, senior author of the study, explained that the hypothesis behind these findings is that tumors and parasites share strategies for resource acquisition and unchecked growth. Therefore, drugs like pyrvinium pamoate, which disrupt these processes, might be repurposed to treat cancers such as MCC. While further research is needed to refine dosing protocols and assess clinical efficacy, these findings open the door to re-evaluate existing antiparasitic medications for oncology applications.

This innovative approach underscores the potential of drug repurposing in oncology, offering hope for improved treatments against challenging cancers like Merkel cell carcinoma. The full study, titled "Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma," was published in the Journal of Clinical Investigation.

For more details, visit source.